IPO raises £7.5m for novel cancer treatment
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings
EquityEquity IPOs

IPO raises £7.5m for novel cancer treatment

Victoria Thiele, 
Aidan Gregory
August 11, 2021 05:40 PM
London Stock Exchange, Paternoster Square, London, England, UK

BiVictriX Therapeutics plc, an emerging biotechnology company that develops new cancer therapies, began trading on London's alternative investment market (Aim) on Wednesday following its IPO.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

Equity IPOsIssue 1716
VT
Victoria Thiele
Senior Reporter - CLOs
Contact
AG
Aidan Gregory
Gift this article